Familiar-Macedo D, de Azeredo E, de Lemos E, Damasco P, de-Oliveira-Pinto L
Vaccines (Basel). 2025; 13(2).
PMID: 40006648
PMC: 11860857.
DOI: 10.3390/vaccines13020101.
Postans M, Pacchiarini N, Song J, Cottrell S, Williams C, Beazer A
PLoS One. 2024; 19(9):e0309645.
PMID: 39240934
PMC: 11379141.
DOI: 10.1371/journal.pone.0309645.
Rousculp M, Hollis K, Ziemiecki R, Odom D, Marchese A, Montazeri M
Vaccines (Basel). 2024; 12(7).
PMID: 39066440
PMC: 11281689.
DOI: 10.3390/vaccines12070802.
Cegolon L, Larese Filon F
Vaccines (Basel). 2024; 12(3).
PMID: 38543888
PMC: 10974058.
DOI: 10.3390/vaccines12030254.
Roa Jr C, de Los Reyes M, Plennevaux E, Smolenov I, Hu B, Gao F
Hum Vaccin Immunother. 2024; 20(1):2301632.
PMID: 38206168
PMC: 10793671.
DOI: 10.1080/21645515.2023.2301632.
Vaccine-induced SARS-CoV-2 antibody response: the comparability of S1-specific binding assays depends on epitope and isotype discrimination.
Schest S, Langer C, Stiegler Y, Karnuth B, Arends J, Stiegler H
Front Immunol. 2023; 14:1257265.
PMID: 37965324
PMC: 10641008.
DOI: 10.3389/fimmu.2023.1257265.
Half dose ChAdOx1 nCoV-19 vaccine was equivalent to full doses to reduce moderate and severe COVID-19 cases.
Galvao-Lima L, de Medeiros Junior N, Jesus G, Morais A, Caldeira-Silva G, Santos J
IJID Reg. 2023; 9:88-94.
PMID: 37953882
PMC: 10637913.
DOI: 10.1016/j.ijregi.2023.09.007.
Evaluation of SARS-CoV-2 infection risks after primary vaccination with BNT162b2, BBIBP-CorV, or ChAdOx1-nCOV-19 and after homologous and heterologous booster vaccinations with these vaccines and evaluation of SARS-CoV-2 reinfection profiles.
Djorwe S, Bousfiha A, Nzoyikorera N, Nyandwi J, Kawthar B, Malki A
Biomedicine (Taipei). 2023; 13(3):31-48.
PMID: 37937059
PMC: 10627210.
DOI: 10.37796/2211-8039.1412.
Comparative Safety and Effectiveness of Heterologous CoronaVac-ChAdOx1 versus Homologous CoronaVac Vaccination in a Real-World Setting: A Retrospective Cohort Study.
Ruenkham A, Uitrakul S, Oberdorfer P, Okonogi S, Katip W
Vaccines (Basel). 2023; 11(9).
PMID: 37766134
PMC: 10535109.
DOI: 10.3390/vaccines11091458.
The role of SARS-CoV-2 N protein in diagnosis and vaccination in the context of emerging variants: present status and prospects.
Song W, Fang Z, Ma F, Li J, Huang Z, Zhang Y
Front Microbiol. 2023; 14:1217567.
PMID: 37675423
PMC: 10478715.
DOI: 10.3389/fmicb.2023.1217567.
Immunogenicity of Mix-and-Match CoronaVac/BNT162b2 Regimen versus Homologous CoronaVac/CoronaVac Vaccination: A Single-Blinded, Randomized, Parallel Group Superiority Trial.
Samoud S, Bettaieb J, Gdoura M, Kharroubi G, Ben Ghachem F, Zamali I
Vaccines (Basel). 2023; 11(8).
PMID: 37631897
PMC: 10459159.
DOI: 10.3390/vaccines11081329.
Comparison of humoral immune response in heterologous and homologous COVID-19 booster vaccine groups using CoronaVac and mRNA-based BNT162b2 vaccines.
Atici S, Soysal A, Gonullu E, Aydemir G, Oner N, Alan S
Rev Soc Bras Med Trop. 2023; 56:e00462023.
PMID: 37493731
PMC: 10367218.
DOI: 10.1590/0037-8682-0046-2023.
Common Adverse Events from Mixing COVID-19 Vaccine Booster in Hanoi, Vietnam.
Van Hung P, Nguyen T, Ha L, Toi P, Tram T
Vaccines (Basel). 2023; 11(6).
PMID: 37376486
PMC: 10304128.
DOI: 10.3390/vaccines11061097.
The COVID-19 experience in Africa and the Middle East.
Bizri A, Al Akoury N, Mhlanga T, Del Carmen Morales G, Haridy H, Hussey G
Ann Med. 2023; 55(1):2222641.
PMID: 37345635
PMC: 10288901.
DOI: 10.1080/07853890.2023.2222641.
Reactogenicity and safety of COVID-19 primary immunisation and booster vaccination regimens: a comparative observational cohort study.
Warkentin L, Werner F, Zeschick N, Kuhlein T, Steininger P, Uberla K
BMC Med. 2023; 21(1):218.
PMID: 37340463
PMC: 10283194.
DOI: 10.1186/s12916-023-02924-5.
Multidimensional futuristic approaches to address the pandemics beyond COVID-19.
Kotwal S, Orekondey N, Saradadevi G, Priyadarshini N, Puppala N, Bhushan M
Heliyon. 2023; 9(6):e17148.
PMID: 37325452
PMC: 10257889.
DOI: 10.1016/j.heliyon.2023.e17148.
Fair-split distribution of multi-dose vaccines with prioritized age groups and dynamic demand: The case study of COVID-19.
Vahdani B, Mohammadi M, Thevenin S, Gendreau M, Dolgui A, Meyer P
Eur J Oper Res. 2023; 310(3):1249-1272.
PMID: 37284206
PMC: 10116158.
DOI: 10.1016/j.ejor.2023.03.032.
Long-Term Cross Immune Response in Mice following Heterologous Prime-Boost COVID-19 Vaccination with Full-Length Spike mRNA and Recombinant S1 Protein.
Li D, Zhao H, Liao Y, Jiang G, Cui P, Zhang Y
Vaccines (Basel). 2023; 11(5).
PMID: 37243067
PMC: 10220924.
DOI: 10.3390/vaccines11050963.
Safety of heterologous ChAdOx1-S/BNT162b2 primary schedule versus homologous BNT162b2 vaccination: Insights from an Italian post-marketing study, 2021.
Fortunato F, Prato R, Iannelli G, Ascatigno L, Loconsole D, Lopalco P
Hum Vaccin Immunother. 2023; 19(1):2209919.
PMID: 37226552
PMC: 10294748.
DOI: 10.1080/21645515.2023.2209919.
Self-reported adverse events after 2 doses of COVID-19 vaccine in Korea.
Kwon Y, Hwang I, Ko M, Kim H, Kim S, Seo S
Epidemiol Health. 2023; 45:e2023006.
PMID: 37183320
PMC: 10266930.
DOI: 10.4178/epih.e2023006.
